Celldex Therapeutics (CLDX) Cash & Equivalents (2010 - 2026)

Celldex Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $35.7 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 108.5% year-over-year to $35.7 million in Q1 2026; TTM through Mar 2026 was $35.7 million, a 108.5% increase from a year earlier, with the FY2025 full-year figure at $28.9 million, up 1.82% from the prior year.
• Cash & Equivalents rose to $35.7 million in Q1 2026 per CLDX's latest filing, from $28.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $115.1 million in Q1 2024 and bottomed at $17.1 million in Q1 2025.
• The 5-year median for Cash & Equivalents is $28.9 million (2025), against an average of $35.5 million.
• Across the five-year window, Cash & Equivalents soared 113.98% in 2023 and sank 85.11% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $29.4 million in 2022, then advanced by 18.3% to $34.8 million in 2023, then dropped by 18.55% to $28.4 million in 2024, then grew by 1.82% to $28.9 million in 2025, then gained by 23.75% to $35.7 million in 2026.
• Per Business Quant, the three latest CLDX Cash & Equivalents figures stand at $35.7 million (Q1 2026), $28.9 million (Q4 2025), and $36.0 million (Q3 2025).